Essa Pharma
Investors/Media

With a focus on the development of small molecule drugs for the treatment of cancer, the goal at ESSA is to develop a pipeline of oncology therapeutics. We will continue to research innovative ideas with the goal of providing a promising future for the patients and community we serve.

With a focus on the development of small molecule drugs for the treatment of cancer, the goal at ESSA is to develop a pipeline of oncology therapeutics. We will continue to research innovative ideas with the goal of providing a promising future for the patients and community we serve.

Latest News
Sep 18, 2023

Recommended Phase 2 dose regimen identified as masofaniten 600mg BID combined with enzalutamide 160mg QD Phase 2 head-to-head portion of the study to commence enrollment immediately Updated Phase...

Aug 31, 2023

ESSA Pharma Inc. (Nasdaq: EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that...

Aug 8, 2023

Completion of the Phase 1 EPI-7386 combination study with Xtandi® (enzalutamide) expected in the third calendar quarter of 2023 followed by initiation of the randomized Phase 2 part of the study...

View All News

Stock Performance

Last Price


Change


Volume

NASDAQEPIX

Investor & Media Contacts

Investor Contact
Xuan Yang
Solebury Strategic Communications
xyang@soleburystrat.com

Media Contact
Zara Lockshin
Solebury Strategic Communications
zlockshin@soleburystrat.com